[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"laparoscopic-cholecystectomy-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:laparoscopic-cholecystectomy-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,76,102,127,157,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100643633","comparison-of-m-tapa-and-external-oblique-intercostal-block-for-intraoperative-opioid-consumption-in-laparoscopic-cholecystectomy-100643633",false,"NCT07595679","Comparison of M-TAPA and External Oblique Intercostal Block for Intraoperative Opioid Consumption in Laparoscopic Cholecystectomy","Comparison of M-TAPA and External Oblique Intercostal Plane Block on Intraoperative Analgesia and Opioid Consumption Guided by Skin Conductance Algesimeter in Laparoscopic Cholecystectomy","MTAPA-EOI","Inclusion Criteria:\n\n* Patients aged 18-80 years\n* ASA physical status I-III\n* Scheduled for elective laparoscopic cholecystectomy under general anesthesia\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patient refusal\n* Known allergy to local anesthetics\n* Chronic opioid use or opioid dependence\n* Neurological or psychiatric disorders affecting pain perception\n* Use of medications affecting autonomic nervous system activity, such as beta-blockers\n* Infection at the injection site\n* Coagulopathy or anticoagulant therapy\n* Pregnancy","ALL","18 Years","80 Years",{"count":21,"type":22},80,"ESTIMATED","OBSERVATIONAL","This prospective observational study is designed to evaluate the effects of modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal (EOI) plane block on intraoperative analgesia and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. Abdominal wall blocks are widely used to improve perioperative analgesia; however, their impact on intraoperative opioid requirements when guided by objective nociception monitoring remains unclear.\n\nAll patients will receive standardized general anesthesia. Intraoperative analgesia will be guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic nervous system activity by measuring fluctuations in skin conductance. The SCA parameter \"peaks per second (PPS)\" will be used to assess nociceptive responses. Remifentanil infusion will be titrated according to SCA values to maintain adequate analgesia. Dose adjustments will be performed at predefined intervals, and changes will be considered valid only if sustained for a minimum duration.\n\nPatients will receive either M-TAPA or EOI block as part of routine clinical practice. The choice of block will not be influenced by the investigators, in accordance with the observational design of the study. Data will be collected prospectively during the intraoperative period and postoperative follow-up.\n\nThe primary outcome of the study is the time-weighted average intraoperative remifentanil infusion rate (µg\u002Fkg\u002Fmin). Secondary outcomes include total intraoperative remifentanil consumption (µg\u002Fkg), intraoperative hemodynamic parameters (heart rate and mean arterial pressure), frequency of deviations in SCA values from the target range, postoperative pain scores assessed using a numeric rating scale (NRS), time to first analgesic requirement, and total rescue analgesic consumption.\n\nPerioperative analgesia will be standardized. All patients will receive intravenous dexketoprofen toward the end of surgery as part of routine clinical practice. Rescue analgesia will be provided with intravenous dexketoprofen when clinically indicated. Additional outcomes include postoperative nausea and vomiting and perioperative complications.\n\nThis study aims to provide objective data on the opioid-sparing effects of different abdominal wall block techniques when intraoperative analgesia is guided by nociception monitoring. The findings may contribute to optimizing analgesic strategies and improving perioperative pain management in laparoscopic surgery.",[26,27],"Laparoscopic Cholecystectomy Surgery","Perioperative Analgesia",[29,30,31,32,33,34,35,36],"M-TAPA","External Oblique Intercostal Block","Abdominal Wall Block","Skin Conductance Algesimeter","Remifentanil","Opioid Consumption","Laparoscopic Cholecystectomy","Intraoperative Analgesia","RECRUITING","2026-06-06",{"date":40,"type":41},"2026-06-09","ACTUAL",{"date":43,"type":41},"2026-05-15",{"date":45,"type":22},"2026-09",{"name":47,"class":48},"Ankara Etlik City Hospital","OTHER_GOV",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100594467","phase-4-esmolol-versus-sufentanil-on-the-quality-of-post-cholecystectomy-recovery-laparoscopic-anaesthesia-with-orotracheal-intubation-on-an-outpatient-basis-100594467","NCT07019818","Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intubation on an Outpatient Basis","Esmolol Versus Sufentanil on the Quality of Recovery After Laparoscopic Cholecystectomy During Anaesthesia With Orotracheal Intubation on an Outpatient Basis","ESA","Inclusion Criteria:\n\n* Adult patients\n* ASA I to III\n* Scheduled outpatient cholecystectomy\n* General anesthesia with orotracheal intubation\n* Patient with signed consent\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Patients on beta-blockers\n* Uncontrolled hypertension\n* Contraindication to beta-blockers\n* Hypersensitivity to the active substance or to one of the excipients of sufentanil and esmolol\n* Pre-existing hemodynamic abnormality\n* Intubation planned to be difficult during the anaesthesia consultation\n* Severe obesity (BMI \\> 35 kg\u002Fm2)\n* Pregnant or breast-feeding women\n* Patients deprived of liberty\n* Patients under guardianship",{"count":59,"type":22},120,"INTERVENTIONAL",[62],"PHASE4","There are 120,000 outpatient laparoscopic cholecystectomies with orotracheal intubation per year in France.\n\nSufentanil is the most commonly used morphine during surgery in France, but morphines have harmful effects when administered for surgery. As with other morphine-based analgesics (painkillers), sufentanil can be associated with nausea and vomiting, confusion, itching and addiction.\n\nThere is an approach to anaesthesia which aims to eliminate the use of morphine in order to avoid its side effects, but there is a lack of clinical trials and benchmarks to provide proof of this.\n\nEsmolol is a cardioselective beta-blocker (a substance that acts only on the heart) which also has marketing authorisation for all types of surgery, the most frequent side effects of which are hypotension and bronchospasm.\n\nThese two drugs have different therapeutic properties for a common objective under general anaesthesia, namely the stability of vital parameters (such as pulse, blood pressure, blood oxygenation, etc.) during surgery.\n\nEsmolol disappears very quickly from the body, which could give it an interesting place in outpatient management.\n\nThe hypothesis tested in this study is that the use of Esmolol is an effective alternative to Sufentanil during general anaesthesia for laparoscopic cholecystectomy with orotracheal intubation on the quality of post-operative recovery and pain.\n\nThe aim of this study is to evaluate whether the use of Esmolol is equivalent to the use of Sufentanil in terms of patient comfort, assessed in terms of quality of recovery, after general anaesthesia with orotracheal intubation for laparoscopic cholecystectomy.",[26],"2026-04-07",{"date":67,"type":41},"2026-04-13",{"date":69,"type":41},"2025-10-29",{"date":71,"type":22},"2028-01-05",{"name":73,"class":74},"University Hospital, Limoges","OTHER",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":60,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100607959","phase-4-comparison-between-standard-and-reduced-doses-of-indocyanine-green-in-fluorescence-cholangiography-during-laparoscopic-cholecystectomy-100607959","NCT07195331","Comparison Between Standard and Reduced Doses of Indocyanine Green in Fluorescence Cholangiography During Laparoscopic Cholecystectomy.","Reduced Dose vs Standard Dose of Indocyanine Green in Near-infrared Fluorescence Cholangiography During Laparoscopic Cholecystectomy: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Signed informed consent.\n* Indication for laparoscopic cholecystectomy (symptomatic cholelithiasis or gallbladder polyps).\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Pregnancy or lactation.\n* Chronic kidney disease (stage \\>IIIb).\n* ICG allergy.\n* Allergy to other iodinated contrast\n* Functional thyroid disease.\n* Emergency non-deferrable surgery.\n* Open approach.\n* Suspicion of gallbladder cancer.\n* Inability to understand the study.",{"count":84,"type":22},122,[62],"Introduction:\n\nThis protocol outlines a randomized phase IV clinical trial designed to compare the efficacy of two different doses of indocyanine green (ICG) used in near-infrared fluorescent cholangiography during laparoscopic cholecystectomy (LC)-the current gold standard treatment for symptomatic cholelithiasis. Despite its effectiveness, LC is still associated with significant risks, particularly bile duct injury (BDI), a severe complication that this study aims to mitigate.\n\nPhase: Phase IV Study design: Multicenter, randomized, open-label, parallel-group clinical trial (modified intention-to-treat).\n\nObjectives:\n\nPrimary objective:\n\n* To analyze differences between treatment groups (standard dose 2.5 mg \\>3h preoperative vs reduced dose 0.25 mg immediate preoperative 15-30 min) during laparoscopic cholecystectomy in:\n* Visualization of extrahepatic biliary structures\n* Degree of visualization\n* Degree of background liver fluorescence interference\n* Perceived utility of the technique\n\nSecondary objectives:\n\n* Influence of BMI, biliary pathology type, surgery type, prior inflammation, surgical difficulty, previous instrumentation, and laparoscopic imaging system on results\n* Intraoperative and postoperative complication rates\n* 30-day mortality\n* Impact on operative time and hospital stay\n* Correlation between subjective and objective fluorescence assessment (ducts-to-liver fluorescence ratio) Population: Patients ≥18 years indicated for laparoscopic cholecystectomy (elective, early or urgent deferred).\n\nMain inclusion criteria:\n\n* Age ≥18 years\n* Signed informed consent\n* Indication for laparoscopic cholecystectomy (symptomatic cholelithiasis, gallbladder polyps with surgical indication)\n\nMain exclusion criteria:\n\n* Age \\\u003C18 years\n* Pregnancy or lactation\n* Chronic kidney disease (stage \\>IIIb)\n* ICG or iodinated contrast allergy\n* Functional thyroid disease\n* Emergency non-deferrable surgery\n* Open approach\n* Suspicion of gallbladder carcinoma\n* Inability to understand the study Investigational product: Indocyanine green (ICG), intravenous administration\n\nThis multicenter study involves two hospitals in Castilla y León, Spain, and plans to enroll 122 adult patients meeting specific clinical criteria for LC. Participants will be randomized into two treatment arms and will receive ICG accordingly:\n\n* Group 1: 2.5 mg \\>3h before surgery\n* Group 2: 0.25 mg 15-30 min before surgery Fluorescence will be assessed both subjectively by the surgical team and objectively through digital image analysis using specialized software to calculate the bile duct-to-liver fluorescence ratio (RFBH).\n\nEndpoints:\n\n* Rates and degree of biliary structure identification pre- and post-dissection\n* Perceived utility of cholangiography\n* Liver background fluorescence interference\n* Ducts-to-liver fluorescence ratio Duration: 12 months recruitment + 1 month follow-up = total 13 months Countries: Spain Ethics: The study will be conducted in accordance with ICH-GCP, EU Clinical Trials Regulation No 536\u002F2014, and applicable national regulations.\n\nBeyond comparing the diagnostic performance of two dosing strategies, this study seeks to provide evidence supporting a more practical and logistically feasible approach for implementing ICG fluorescence cholangiography in routine surgical practice, without compromising diagnostic accuracy or patient safety.",[26],[89,90,91,92],"laparoscopic cholecystectomy","bile ducts","cholangiography","indocyanine green","2026-03-06",{"date":95,"type":41},"2026-03-09",{"date":97,"type":41},"2026-02-26",{"date":99,"type":22},"2027-01-31",{"name":101,"class":74},"Instituto de Investigación Biomédica de Salamanca",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":60,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100625654","phase-4-attenuate-the-stress-response-in-laparoscopic-cholecystectomy-100625654","NCT07425444","Attenuate the Stress Response in Laparoscopic Cholecystectomy","Dexmedetomidine Versus Fentanyl-Midazolam Combination to Attenuate the Stress Response in Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Age 18-65 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I - II.\n\nExclusion Criteria:\n\n* Known allergy to study drugs.\n* Uncontrolled, non-correctable comorbidities (hepatic, renal or cardiac such as hypertension \\& Arrhythmia ).\n* History of psychiatric illness or substance abuse.\n* Pregnancy or lactation","65 Years",{"count":111,"type":22},50,[62],"Aims of this study are to compare the effectiveness of dexmedetomidine versus fentanyl-midazolam in attenuating hemodynamic stress response during laparoscopic cholecystectomy (mainly HR). And to assess the recovery profile, the pain and opioid requirements, the sedation profile, and any adverse events during the first 24 hrs postoperatively",[26],[116],"stress response","NOT_YET_RECRUITING","2026-02-19",{"date":120,"type":41},"2026-02-20",{"date":122,"type":22},"2026-02",{"date":124,"type":22},"2027-04",{"name":126,"class":74},"Assiut University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":17,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":60,"phases":139,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":49},"100624442","phase-4-pain-relief-following-laparoscopic-cholecystectomy-while-comparing-intra-abdominal-versus-sub-cutaneous-local-anesthetic-administration-100624442","NCT07409688","Pain Relief Following Laparoscopic Cholecystectomy While Comparing Intra Abdominal Versus Sub Cutaneous Local Anesthetic Administration","Comparative Evaluation of Analgesic Outcomes of Intra-peritoneal Versus Subcutaneous Infiltration of Bupivacaine for Laparoscopic Cholecystectomy Patients \"","Inclusion Criteria:\n\n* ASA I and II\n\nExclusion Criteria:\n\n* Allergic to local anesthetic Open cholecystectomy History of chronic pain History of abdominal surgery",true,"15 Years","60 Years",{"count":138,"type":22},100,[62],"Laparoscopic cholecystectomy involves removal of gallbladder through small incision ports resulting in faster recovery. Small incisions are less painful and hence local anesthesis administered can be effective for pain management. This local anesthetic can be administered either within abdominal cavity or at sit of small incisions.",[26,142,143],"Analgeisa","Local Anesthetic Infiltration",[145,146,147],"Laparoscopic cholecystectomy","Post Operative analgesia","Local anesthetic administration","2026-02-12",{"date":150,"type":41},"2026-02-13",{"date":152,"type":41},"2026-01-17",{"date":154,"type":22},"2026-06-17",{"name":156,"class":74},"Rawalpindi Medical College",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":164,"targetDuration":165,"studyType":23,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":49},"100616286","effects-of-the-4-7-8-breathing-technique-on-postoperative-pain-scores-anxiety-and-sleep-quality-in-patients-100616286","NCT07303634","Effects of the 4-7-8 Breathing Technique on Postoperative Pain Scores, Anxiety, and Sleep Quality in Patients","Effects of the 4-7-8 Breathing Technique, One of the Deep Breathing Techniques, on Postoperative Pain Scores, Anxiety, and Sleep Quality in Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n1. Participants must be informed and give voluntary consent to participate in the study.\n2. Patients who have undergone laparoscopic cholecystectomy.\n3. Patients with an ASA physical performance score of 1-3.\n4. Patients aged 18-65 years.\n\nExclusion Criteria:\n\n1. Patients who do not wish to continue participating in the study\n2. Patients whose medical condition has deteriorated.\n3. Those with a history of medication use accompanied by depression and other psychiatric diagnoses\n4. Those with a history of substance dependence\n5. Those with respiratory tract infection or pathology (Asthma, COPD)\n6. Those with neuromuscular disorders\n7. Those under the age of 18\n8. Patients who cannot read or write Turkish or who are uncooperative\n9. Those unable to adapt to breathing training techniques\n10. Conversion from laparoscopic surgery to laparotomy",{"count":138,"type":22},"1 Day","This study aims to evaluate the effects of teaching the 4-7-8 breathing technique, one of the deep breathing techniques, to patients undergoing laparoscopic cholecystectomy surgery and applying it during the preoperative and postoperative periods on postoperative pain levels, anxiety levels, and sleep quality. Secondary objectives are to evaluate patients' postoperative peripheral oxygen saturation and length of hospital stay.\n\nPatients will be randomized into two groups using a closed opaque envelope technique, and the groups will be determined. This procedure will be performed by a researcher not involved in the study. Patients undergoing Laparoscopic Cholecystectomy will be randomized. The groups will be coded as A and B. Group A patients will be instructed to practice the 4-7-8 breathing technique for 6 hours per day, 10 cycles per hour, during the preoperative and postoperative periods after receiving training. Group B will be the control group, and routine follow-ups will be performed on these patients. Participants' correct and regular application of the breathing technique will be verified through a short test after training and follow-up calls. Participants will be given an \"Informed Consent Form,\" and their consent will also be obtained not to interact with each other or share group information. The perioperative process will be monitored by anesthesiologists not involved in the study.",[26],[89,169,170,171],"respiratory physiotherapy","visual analog scale","The Richards-Campbell Sleep Questionnaire","2025-12-18",{"date":174,"type":41},"2025-12-26",{"date":176,"type":22},"2025-12-15",{"date":178,"type":22},"2026-02-01",{"name":180,"class":48},"Konya Beyhekim Training and Research Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":60,"phases":189,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100580542","phase-3-beneficial-effects-of-low-dose-intravenous-dexmedetomidine-premedication-in-patient-undergoing-laparoscopic-cholecystectomy-under-general-anesthesia-100580542","NCT06838650","Beneficial Effects of Low-Dose Intravenous Dexmedetomidine Premedication in Patient Undergoing Laparoscopic Cholecystectomy Under General Anesthesia","Inclusion Criteria:\n\n* age 18-64 years with planned LC\n* American Society of Anesthesiologists (ASA) physical status of Grade I or II\n* body mass index (BMI) of 20-30 kg\u002Fm2 .\n\nExclusion Criteria:\n\n* severe cardiovascular\n* cerebrovascular disease\n* severe endocrine\n* liver, kidney\n* neurological\n* blood system disease\n* preoperative respiratory infection or asthma\n* history of opioid addiction\n* allergy to the drugs used in this study\n* psychosocial disease or cognitive dysfunction.\n* incomplete case report form or lost to follow-up and failed to undergo an effectiveness and safety assessment\n* LC converted to open surgery\n* severe hemodynamic instability during surgery\n* surgical duration \\>2 h .","64 Years",{"count":138,"type":22},[190],"PHASE3","Laparoscopic cholecystectomy (LC) is considered the standard treatment for gallbladder disease.1 Compared to open cholecystectomy, LC is the preferred treatment approach because it is associated with less surgical trauma, shorter hospital stays, and faster postoperative recovery.2 However, the elevated intra-abdominal pressure due to pneumoperitoneum can cause various stress responses that affect patient prognosis and present a severe challenge in anesthetic management.3 Therefore, the search for an optimal anesthetic protocol to minimize adverse reactions during LC remains critical.\n\nDexmedetomidine (Dex), a potent and highly selective α2-adrenergic receptor agonist, presents sedative, analgesic, anesthetic, and sympatholytic properties, without causing respiratory depression, when used in an appropriate dose range.4 Numerous studies have suggested that Dex can effectively attenuate the surgical stress response and provide intraoperative hemodynamic stability.5 Furthermore, it has been shown to reduce anesthetic requirements and improve the quality of patient recovery.6,7 Hence, it has been widely used as an adjuvant during general anesthesia.\n\nNevertheless, the clinical effects of Dex remain controversial. Some studies have shown that the anesthesia recovery time is prolonged and the incidence of bradycardia increases significantly after intravenous Dex infusion.8-10 This is mainly attributed to the different doses and methods of Dex administration. Although the complications are always transient and reversible, timely attention is required to avoid serious adverse consequences. To enhance the value of Dex for clinical application and improve the quality of general anesthesia, the more appropriate protocol of Dex administra- tion need to be explored. The elimination half-life of Dex is approximately 2 h, with a rapid distribution half-life of approximately 6 min.11 Most LC procedures are completed within 1 h; therefore, to reduce postoperative complications and shorten postoperative recovery time, we prefer preoperative Dex loading to intraoperative continuous Dex infusion. According to our previous data, the anesthesia awakening time will be prolonged and the incidence of bradycardia increased significantly when 1.0 µg\u002Fkg of Dex will be administered before general anesthesia induction. This prospective, double-blind, randomized controlled trial aimed to determine the efficacy of low-dose (0.5 µg\u002Fkg) intravenous Dex premedication on hemodynamics and adverse events during general anesthesia. We aimed to confirm the efficacy of low- dose intravenous Dex premedication in patients under general anesthesia during LC and to provide a data reference for the clinical application of Dex in further research. Dexmedetomidine (Dex) is a potent and highly selective α2-adrenergic receptor agonist. Within an appropriate dose range, Dex can effectively attenuate the surgical stress response, provide intraoperative hemodynamic stability, and improve the patient recovery quality. High-dose Dex can delay patient awakening from anesthesia and increase the incidence of bradycardia. This randomized controlled trial aimed to investigate the effects of low-dose intravenous Dex premedication in patients undergoing laparoscopic cholecystectomy (LC).",[26],[194],"Dexmedetomidine","2025-02-19",{"date":197,"type":41},"2025-02-21",{"date":199,"type":22},"2025-03-01",{"date":201,"type":22},"2026-06-01",{"name":126,"class":74}]